The post Generic Drugs Are The Physical Manifestation Of Lifesaving Abundance appeared on BitcoinEthereumNews.com. CHICAGO – JULY 23: Lipitor tablets sit in a tray at a Pharmacy July 23, 2008 in Chicago, Illinois. Pfizer, the world’s biggest drug maker and manufacturer of the cholesterol drug Lipitor, said today its second quarter profit rose to $2.78 billion. Lipitor is the world’s top-selling drug. (Photo by Scott Olson/Getty Images) Getty Images Ludwig von Mises long ago observed that the notion of luxury is entirely historical. The previous truth is important to remember as Sens. Rick Scott (R-FL) and Kirsten Gillibrand (D-NY) take aim at generic drugs. For the senators to question the safety and quality of generics whether produced stateside or overseas is for them to question the brilliant evolution of all market advances that ultimately expand access to goods formerly inaccessible to all but the richest of the rich, if at all. Cars once driven by the very rich were rendered plentiful by Henry Ford given his desire to manufacture them for “the great multitude.” The first IBM mainframe computer in the 1960s fetched over $1 million dollars, only for visionaries like Michael Dell to become billionaires by virtue of mass-producing computers similarly available to “the great multitude.” In 1983, Motorola launched the first mobile phone for $3,995, while today we have supercomputers in our pockets that transmit calls for us, in addition to thousands of other features. Which is why pharmaceutical advance is so important. No doubt politicians can and do blanch at the dollars expended on innovations meant to mitigate the horrors of cancer, heart disease, Alzheimer’s and countless other maladies, but the people invariably benefit. And this is true even if it’s similarly true that initial pharmaceutical leaps gift the very few very well to do with drugs not available to the broader population. We should cheer such an outcome, and for… The post Generic Drugs Are The Physical Manifestation Of Lifesaving Abundance appeared on BitcoinEthereumNews.com. CHICAGO – JULY 23: Lipitor tablets sit in a tray at a Pharmacy July 23, 2008 in Chicago, Illinois. Pfizer, the world’s biggest drug maker and manufacturer of the cholesterol drug Lipitor, said today its second quarter profit rose to $2.78 billion. Lipitor is the world’s top-selling drug. (Photo by Scott Olson/Getty Images) Getty Images Ludwig von Mises long ago observed that the notion of luxury is entirely historical. The previous truth is important to remember as Sens. Rick Scott (R-FL) and Kirsten Gillibrand (D-NY) take aim at generic drugs. For the senators to question the safety and quality of generics whether produced stateside or overseas is for them to question the brilliant evolution of all market advances that ultimately expand access to goods formerly inaccessible to all but the richest of the rich, if at all. Cars once driven by the very rich were rendered plentiful by Henry Ford given his desire to manufacture them for “the great multitude.” The first IBM mainframe computer in the 1960s fetched over $1 million dollars, only for visionaries like Michael Dell to become billionaires by virtue of mass-producing computers similarly available to “the great multitude.” In 1983, Motorola launched the first mobile phone for $3,995, while today we have supercomputers in our pockets that transmit calls for us, in addition to thousands of other features. Which is why pharmaceutical advance is so important. No doubt politicians can and do blanch at the dollars expended on innovations meant to mitigate the horrors of cancer, heart disease, Alzheimer’s and countless other maladies, but the people invariably benefit. And this is true even if it’s similarly true that initial pharmaceutical leaps gift the very few very well to do with drugs not available to the broader population. We should cheer such an outcome, and for…

Generic Drugs Are The Physical Manifestation Of Lifesaving Abundance

2025/10/29 02:21

CHICAGO – JULY 23: Lipitor tablets sit in a tray at a Pharmacy July 23, 2008 in Chicago, Illinois. Pfizer, the world’s biggest drug maker and manufacturer of the cholesterol drug Lipitor, said today its second quarter profit rose to $2.78 billion. Lipitor is the world’s top-selling drug. (Photo by Scott Olson/Getty Images)

Getty Images

Ludwig von Mises long ago observed that the notion of luxury is entirely historical. The previous truth is important to remember as Sens. Rick Scott (R-FL) and Kirsten Gillibrand (D-NY) take aim at generic drugs. For the senators to question the safety and quality of generics whether produced stateside or overseas is for them to question the brilliant evolution of all market advances that ultimately expand access to goods formerly inaccessible to all but the richest of the rich, if at all.

Cars once driven by the very rich were rendered plentiful by Henry Ford given his desire to manufacture them for “the great multitude.” The first IBM mainframe computer in the 1960s fetched over $1 million dollars, only for visionaries like Michael Dell to become billionaires by virtue of mass-producing computers similarly available to “the great multitude.” In 1983, Motorola launched the first mobile phone for $3,995, while today we have supercomputers in our pockets that transmit calls for us, in addition to thousands of other features.

Which is why pharmaceutical advance is so important. No doubt politicians can and do blanch at the dollars expended on innovations meant to mitigate the horrors of cancer, heart disease, Alzheimer’s and countless other maladies, but the people invariably benefit. And this is true even if it’s similarly true that initial pharmaceutical leaps gift the very few very well to do with drugs not available to the broader population. We should cheer such an outcome, and for obvious reasons.

As the formerly inaccessible car, computer, and mobile phone make blindingly plain, the luxuries of the very rich foretell what we’ll all enjoy if markets are free. It’s that simple.

Which is the point of generic drugs. They’re brilliant pharmaceutical representations of what’s true in all walks of profit-motivated life. What’s expensive in the near-term, and as pharmaceutical companies recoup the enormous costs associated with funding their intrepid leaps, eventually is not.

All of which helps explain why 90 percent of pharmaceutical prescriptions filled are generic. It’s an essential progression.

Which is why pushback against Sens. Scott and Gillibrand is so necessary. For them to attack generic drugs, and in particular foreign-produced generics is for the senators to attack a progression that has long democratized access to life-enhancing and life-saving drugs. Worse, it’s an attack on the evolution of all market advances that are invariably an effect of globalized production.

At which point it’s quite simply odd that Scott would call into question the validity of the FDA’s inspections of foreign generics. The questioning implies an easy FDA that is belied by history, and that Republicans have long criticized as too stringent.

For now, healthcare and the drugs associated with it are frequently expensive. Which is the point. What’s great has to be initially expensive, but much more importantly, what’s inexpensive and accessible to all must initially be quite costly.

Thank goodness for the globalized production that eventually turns costly scarcity into abundance. Scott and Gillibrand should be thankful too, and retrieve legislation meant to suffocate the democratization of what improves life, and often saves it too.

Source: https://www.forbes.com/sites/johntamny/2025/10/28/generic-drugs-are-the-physical-manifestation-of-democratized-abundance/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights

You May Also Like

Galaxy Digital confirms leveraging Aave for capital efficiency and next-gen DeFi solutions

Galaxy Digital confirms leveraging Aave for capital efficiency and next-gen DeFi solutions

The post Galaxy Digital confirms leveraging Aave for capital efficiency and next-gen DeFi solutions appeared on BitcoinEthereumNews.com. The company is using Aave to optimize liquidity, manage treasury, and build innovative DeFi products. The development signals the prevailing institutional shift towards DeFi. AAVE has gained more than 5% on the news. Altcoins remained on the radar as they continue to outperform Bitcoin after the September 17 interest rate cut. Amidst the optimism, publicly listed Galaxy Digital has confirmed significant integration with Aave, a leading lending protocol. The financial services company announced that Aave is key to its strategic operations, including treasury undertakings, trading, and lending. The approach aims to reduce dependence on centralized liquidity providers and enhance capital efficiency. According to Galaxy’s Head of Lending, Max Bareiss: Aave has proven to be a highly reliable platform for accessing liquidity. It’s a core venue for borrowing stablecoins against blue-chip assets like BTC and ETH, offering 24/7 availability, without third-party intermediaries. As institutions embrace digital assets, DeFi is emerging as critical financial infrastructure. At Galaxy, we’re integrating @aave into our workflows, not just to manage liquidity, but to transform how capital moves across markets👇 pic.twitter.com/vb00R12BaJ — Galaxy (@galaxyhq) September 18, 2025 Aave’s native token rallied after Galaxy’s announcement, which testified to DeFi’s increasing institutional appeal. Borrowing against top assets The firm primarily uses Aave to borrow stablecoins against established assets like Bitcoin and Ethereum. Leveraging a permissionless network allows Galaxy to escape slow authorization procedures seen in CeFi. That enables its trading desks to access massive liquidity instantly. Meanwhile, the firm uses the borrowed capital to support balance sheet liquidity, institutional lending, and client trading activities. That gives Galaxy a competitive edge in the fast-paced blockchain markets. Furthermore, Aave serves as Galaxy’s credit facility, with its thriving lending pools supporting flexible credit and bridge loans. The blockchain’s accommodative interest rate mechanism allows the company to manage borrowing costs according to…
Share
2025/09/19 01:34